Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus AVENTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus AVENTYL.
AMITID vs AVENTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant